title: [Chronic cerebrovascular diseases associated with metabolic syndrome: new treatment approaches].
abstract: Metabolic syndrome is a risk factor for acute and chronic cerebrovascular diseases. The development of oxidative stress promotes the progression of cerebral ischemia and treatment of the biochemical disturbances is needed. Use of antioxidants in patients with cerebrovascular diseases and metabolic syndrome reduce such symptoms as insulin resistance, hyperglyceridemia, hyperglycemia. The authors present results of a clinical study of mexidol in 40 patients, aged from 50 to 70 years, with chronic cerebrovascular pathology. Perspectives of using this group of drugs as universal neuroprotectors are discussed.
authors.forename: M M
authors.initials: MM
authors.lastname: Tanashian
authors.forename: O V
authors.initials: OV
authors.lastname: Lagoda
authors.forename: K V
authors.initials: KV
authors.lastname: Antonova
mesh_terms: D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications*; D008875:Middle Aged; D010847:Picolines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D010847:Picolines; C070020:emoxypine succinate